| A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report. | |
| | |
MedLine Citation:
|
PMID: 20010473 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Chronic myeloid neoplasm with eosinophilia and abnormalities of platelet-derived growth factor receptor alpha (PDGFRA), referred to until 2008 as chronic eosinophilic leukemia, is distinguished from hypereosinophilic syndrome (HES), if accompanied by genetic abnormalities that enable to determine eosinophil clonality. Typically, HES has a benign course and glucocorticosteroids suffice to achieve remission. In chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA the FIP1L1-PDGFRA fusion gene can be detected. Its product is a protein showing tyrosine kinase activity leading to malignant proliferation of eosinophil precursors. Differential diagnosis of HES is often difficult because hypereosinophilia may also be reactive and may occur in many nonhematological as well as hematological disorders. Thus, reverse-transcription polymerase chain reaction (RT-PCR)is indicated in all patients with HES in order to detect the FIP1L1-PDGFRA transcript. Traditional treatment of chronic myeloid neoplasm with cytostatic drugs results in a short-term and transient remission or stabilization of the disease. We present the case of a 52-year-old patient with chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA, in whom acceleration occurred after a year of cytostatic therapy with hydroxyurea and was successfully treated with imatinib. It was impossible to unequivocally determine the type of bone marrow disease based on histologic criteria, and a wide spectrum of molecular tests differentiating the type of myeloid proliferation were necessary to establish the diagnosis. RT-PCR did not reveal BCR-ABL or JAK2 V617F mutation. Further molecular testing showed rearrangement involving the FIP1L1 gene, thus enabling implementation of targeted therapy. |
| | |
Authors:
|
Marek Rodzaj; Krystyna Ga?azka; Miros?aw Majewski; Andrzej Zdu?czyk |
Related Documents
:
|
1410563 - Atypical arteriographic features of myositis ossificans circumscripta (moc). 15554383 - Ct characteristics of primary retroperitoneal neoplasms. 1846993 - Cytomegalic inclusion disease: intrauterine sonographic diagnosis using findings involv... |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Polskie Archiwum Medycyny Wewn?trznej Volume: 119 ISSN: 1897-9483 ISO Abbreviation: Pol. Arch. Med. Wewn. Publication Date: 2009 Dec |
Date Detail:
|
Created Date: 2009-12-17 Completed Date: 2010-05-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0401225 Medline TA: Pol Arch Med Wewn Country: Poland |
Other Details:
|
Languages: eng Pagination: 838-41 Citation Subset: IM |
Affiliation:
|
Department of Hematology and Internal Diseases, Rydygier Hospital, Krak?w, Poland. rodzaj@mp.pl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
administration & dosage Disease Progression Gene Rearrangement Humans Hypereosinophilic Syndrome / diagnosis*, drug therapy*, genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis*, drug therapy*, genetics Middle Aged Oncogene Proteins, Fusion / metabolism* Piperazines / administration & dosage* Protein Kinase Inhibitors / administration & dosage Pyrimidines / administration & dosage* Receptor, Platelet-Derived Growth Factor alpha / metabolism* mRNA Cleavage and Polyadenylation Factors / metabolism* |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/FIP1L1-PDGFRA fusion protein, human; 0/Oncogene Proteins, Fusion; 0/Piperazines; 0/Protein Kinase Inhibitors; 0/Pyrimidines; 0/mRNA Cleavage and Polyadenylation Factors; 152459-95-5/imatinib; EC 2.7.10.1/Receptor, Platelet-Derived Growth Factor alpha |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Peritoneal dialysis as a therapeutic approach in congestive heart failure resistant to pharmacologic...
Next Document: Oral signs in the diagnosis of celiac disease: review of the literature.